Literature DB >> 23681962

CROI 2013: Advances in antiretroviral therapy.

Barbara S Taylor1, Timothy J Wilkin, Noga Shalev, Scott M Hammer.   

Abstract

The 20th Conference on Retroviruses and Opportunistic Infections (CROI) presented important highlights of advances in antiretroviral therapy. Investigators emphasized new approaches to finding a cure for HIV infection, with a special focus on an infant who received combination antiretroviral therapy at 30 hours of age and may have achieved a functional cure in the absence of continued antiretroviral therapy. Challenges and opportunities for sustainable antiretroviral therapy under the Patient Protection and Affordable Care Act (PPACA) were discussed, and investigators around the globe examined attrition through the cascade of care for HIV disease and its implications. Knowledge of barriers to antiretroviral therapy in resource-limited settings (RLSs) continues to expand, as do innovative strategies for improving antiretroviral therapy access and uptake in these settings. Encouraging results from expanded prevention of mother-to-child transmission programs, including option B+, were presented. Prevalence of transmitted (primary) drug resistance appears to be increasing in the United States, and new detection techniques may increase access to resistance testing in RLSs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681962      PMCID: PMC6148870     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  7 in total

1.  A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

Authors:  Timothy J Wilkin; Christina M Lalama; John McKinnon; Rajesh T Gandhi; Nina Lin; Alan Landay; Heather Ribaudo; Lawrence Fox; Judith S Currier; John W Mellors; Roy Gulick; Allan R Tenorio
Journal:  J Infect Dis       Date:  2012-06-27       Impact factor: 5.226

2.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

3.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Jennifer F Hoy; Amalio Telenti; Constance Benson; Pedro Cahn; Joseph J Eron; Huldrych F Günthard; Scott M Hammer; Peter Reiss; Douglas D Richman; Giuliano Rizzardini; David L Thomas; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

4.  Vital signs: HIV prevention through care and treatment--United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-12-02       Impact factor: 17.586

5.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

6.  Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach.

Authors:  Elvin H Geng; David R Bangsberg; Nicolas Musinguzi; Nneka Emenyonu; Mwebesa Bosco Bwana; Constantin T Yiannoutsos; David V Glidden; Steven G Deeks; Jeffrey N Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

7.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

  7 in total
  6 in total

1.  RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.

Authors:  Wenhui Hu; Rafal Kaminski; Fan Yang; Yonggang Zhang; Laura Cosentino; Fang Li; Biao Luo; David Alvarez-Carbonell; Yoelvis Garcia-Mesa; Jonathan Karn; Xianming Mo; Kamel Khalili
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

2.  Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system.

Authors:  E J Edelman; J P Tate; D A Fiellin; S T Brown; K Bryant; N Gandhi; C L Gibert; M B Goetz; K S Gordon; M C Rodriguez-Barradas; R S Braithwaite; D Rimland; A C Justice
Journal:  HIV Med       Date:  2015-02-17       Impact factor: 3.180

Review 3.  Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals.

Authors:  Angélica Saraí Jiménez-Osorio; Sinaí Jaen-Vega; Eduardo Fernández-Martínez; María Araceli Ortíz-Rodríguez; María Fernanda Martínez-Salazar; Reyna Cristina Jiménez-Sánchez; Olga Rocío Flores-Chávez; Esther Ramírez-Moreno; José Arias-Rico; Felipe Arteaga-García; Diego Estrada-Luna
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

Review 4.  Eradication of HIV and Cure of AIDS, Now and How?

Authors:  Jielin Zhang; Clyde Crumpacker
Journal:  Front Immunol       Date:  2013-10-18       Impact factor: 7.561

5.  High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada.

Authors:  Lillian Lourenço; Guillaume Colley; Bohdan Nosyk; Dmitry Shopin; Julio S G Montaner; Viviane D Lima
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  Factors Determining Survival and Retention among HIV-Infected Children and Adolescents in a Community Home-Based Care and a Facility-Based Family-Centred Approach in Kampala, Uganda: A Cohort Study.

Authors:  W Massavon; L Barlow-Mosha; L Mugenyi; W McFarland; G Gray; R Lundin; P Costenaro; M M Nannyonga; M Penazzato; D Bagenda; C P Namisi; D Wabwire; M Mubiru; S Kironde; D Bilardi; A Mazza; M G Fowler; P Musoke; C Giaquinto
Journal:  ISRN AIDS       Date:  2014-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.